Grifols Sa ADR (GIKLY) 25.8300 $GIKLY
Grifols introduces the AlphaKit(R) QuickScreen, a novel point-of-care screening device to detect alpha1-antitrypsin (AAT) deficiency, a leading cause of genetic emphysema / COPD in adults
PR Newswire Europe - Mon Sep 09, 3:01AM CDT
-- Details presented at the annual congress of the European Respiratory Society (ERS)
Grifols Announces Winners of the 10th Annual eALTA Research Fellowship at 2013 ERS Congress
PR Newswire Europe - Mon Sep 09, 3:00AM CDT
- Awards fund early career investigators' research to advance understanding and treatment of alpha1-antitrypsin deficiency.
California State Legislature recognizes Grifols for its Decennial Anniversary in California
PR Newswire - Mon Aug 12, 1:11PM CDT
Today Grifols was honored at the California State Legislature by state Senator Kevin de Leon (D-Los Angeles) and Assembly Member Jimmy Gomez (D- East Los Angeles) marking the 10th Anniversary of the Company's establishment of its U.S. headquarters in Los Angeles, and a decade of conducting business in California and improving the health and well-being of people around the world.
Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
PR Newswire Europe - Thu Jul 18, 7:47AM CDT
Grifols, a global healthcare company based in Barcelona, Spain with more than 15 years of innovation and expertise with automated drug storage and dispensing solutions in European hospital pharmacies, has now implemented its first automated inventory management carousel project in the United States.
Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
PR Newswire - Wed May 22, 7:47AM CDT
Grifols, a global healthcare company based in Barcelona, Spain, presented results from a study demonstrating that a higher dose of PROLASTIN©-C (Alpha1-Proteinase Inhibitor [Human]) increased levels of the alpha1 protein in patients with alpha1antitrypsin (AAT) deficiency to levels that are considered within the normal range for healthy individuals. AAT deficiency is a life-threatening, genetic condition in which low levels of the alpha1 proteinase inhibitor (A1PI) protein can lead to emphysema.
Annual Report for 2012 on Form 20-F filed with the SEC on April 5, 2013
PR Newswire - Fri Apr 05, 11:29AM CDT
Grifols, S.A. ("Grifols"
(MCE:GRF, MCE:GRF.P and NASDAQ: GRFS), announced that it has filed its 2012 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC" on April 5, 2013. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2012.
Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection
PR Newswire - Wed Mar 06, 7:23PM CST
Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags. Previously, Cadence announced the extension of its supply arrangement for OFIRMEV in glass vials with Lawrence Laboratories, a member of the Bristol Myers Squibb group of companies, through December 31, 2018. Additionally, the company has terminated its development and supply agreement for OFIRMEV in glass vials with Baxter Healthcare Corporation.
PROLASTIN(R) celebrates 25 years as leading augmentation therapy for treatment of alpha(1)-antitrypsin deficiency
PR Newswire Europe - Tue Feb 05, 11:36AM CST
- Grifols to commemorate anniversary by sponsoring events and programs to promote awareness and research
PROLASTIN® celebrates 25 years as leading augmentation therapy for treatment of alpha(1)-antitrypsin deficiency
PR Newswire - Tue Feb 05, 11:30AM CST
Grifols, a global healthcare company based in Barcelona, Spain, is commemorating the 25th anniversary year of PROLASTIN® (alpha1-proteinase inhibitor [human]) and the 50th anniversary of the discovery of alpha1-antitrypsin deficiency (Alpha1) with a series of events and programs around the world aimed at raising awareness and advancing research into the treatment of alpha1. This rare and life-threatening disease causes genetic emphysema due to low circulating levels of the alpha1-antitrypsin protein.
Grifols introduces the AlphaKit(R) QuickScreen, a novel point-of-care screening device to detect alpha1-antitrypsin (AAT) deficiency, a leading cause of genetic emphysema / COPD in adults
PR Newswire Europe - Mon Sep 09, 3:01AM CDT
-- Details presented at the annual congress of the European Respiratory Society (ERS)
Grifols Announces Winners of the 10th Annual eALTA Research Fellowship at 2013 ERS Congress
PR Newswire Europe - Mon Sep 09, 3:00AM CDT
- Awards fund early career investigators' research to advance understanding and treatment of alpha1-antitrypsin deficiency.
California State Legislature recognizes Grifols for its Decennial Anniversary in California
PR Newswire - Mon Aug 12, 1:11PM CDT
Today Grifols was honored at the California State Legislature by state Senator Kevin de Leon (D-Los Angeles) and Assembly Member Jimmy Gomez (D- East Los Angeles) marking the 10th Anniversary of the Company's establishment of its U.S. headquarters in Los Angeles, and a decade of conducting business in California and improving the health and well-being of people around the world.
Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
PR Newswire Europe - Thu Jul 18, 7:47AM CDT
Grifols, a global healthcare company based in Barcelona, Spain with more than 15 years of innovation and expertise with automated drug storage and dispensing solutions in European hospital pharmacies, has now implemented its first automated inventory management carousel project in the United States.
Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
PR Newswire - Wed May 22, 7:47AM CDT
Grifols, a global healthcare company based in Barcelona, Spain, presented results from a study demonstrating that a higher dose of PROLASTIN©-C (Alpha1-Proteinase Inhibitor [Human]) increased levels of the alpha1 protein in patients with alpha1antitrypsin (AAT) deficiency to levels that are considered within the normal range for healthy individuals. AAT deficiency is a life-threatening, genetic condition in which low levels of the alpha1 proteinase inhibitor (A1PI) protein can lead to emphysema.
Annual Report for 2012 on Form 20-F filed with the SEC on April 5, 2013
PR Newswire - Fri Apr 05, 11:29AM CDT
Grifols, S.A. ("Grifols"
(MCE:GRF, MCE:GRF.P and NASDAQ: GRFS), announced that it has filed its 2012 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC" on April 5, 2013. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2012. Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection
PR Newswire - Wed Mar 06, 7:23PM CST
Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags. Previously, Cadence announced the extension of its supply arrangement for OFIRMEV in glass vials with Lawrence Laboratories, a member of the Bristol Myers Squibb group of companies, through December 31, 2018. Additionally, the company has terminated its development and supply agreement for OFIRMEV in glass vials with Baxter Healthcare Corporation.
PROLASTIN(R) celebrates 25 years as leading augmentation therapy for treatment of alpha(1)-antitrypsin deficiency
PR Newswire Europe - Tue Feb 05, 11:36AM CST
- Grifols to commemorate anniversary by sponsoring events and programs to promote awareness and research
PROLASTIN® celebrates 25 years as leading augmentation therapy for treatment of alpha(1)-antitrypsin deficiency
PR Newswire - Tue Feb 05, 11:30AM CST
Grifols, a global healthcare company based in Barcelona, Spain, is commemorating the 25th anniversary year of PROLASTIN® (alpha1-proteinase inhibitor [human]) and the 50th anniversary of the discovery of alpha1-antitrypsin deficiency (Alpha1) with a series of events and programs around the world aimed at raising awareness and advancing research into the treatment of alpha1. This rare and life-threatening disease causes genetic emphysema due to low circulating levels of the alpha1-antitrypsin protein.
